Evonik Hones Pharma Focus with Sale of U.K. Unit

Evonik says the recent sale of its Seal Sands, U.K. fine chemical facility and the planned introduction in the next few weeks of a pharmaceutical ingredient facility at Nanning, China will “significantly” increase its active pharma ingredient (API) production capacity while reducing its exposure to potentially lower-value non-GMP material production. Also, the Seal Sands divestment was made without the Evonik group losing any chemistries, Rudolf Hanko, head of Evonik’s Exclusive Synthesis & Amino Acids business line, tells CW. Evonik...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers